Cite
Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
MLA
Haixia Fu, et al. “Mesenchymal Stromal Cells plus Basiliximab Improve the Response of Steroid-Refractory Acute Graft-versus-Host Disease as a Second-Line Therapy: A Multicentre, Randomized, Controlled Trial.” BMC Medicine, vol. 22, no. 1, Feb. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12916-024-03275-5.
APA
Haixia Fu, Xueyan Sun, Ren Lin, Yu Wang, Li Xuan, Han Yao, Yuanyuan Zhang, Xiaodong Mo, Meng lv, Fengmei Zheng, Jun Kong, Fengrong Wang, Chenhua Yan, Tingting Han, Huan Chen, Yao Chen, Feifei Tang, Yuqian Sun, Yuhong Chen, & Lanping Xu. (2024). Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. BMC Medicine, 22(1), 1–15. https://doi.org/10.1186/s12916-024-03275-5
Chicago
Haixia Fu, Xueyan Sun, Ren Lin, Yu Wang, Li Xuan, Han Yao, Yuanyuan Zhang, et al. 2024. “Mesenchymal Stromal Cells plus Basiliximab Improve the Response of Steroid-Refractory Acute Graft-versus-Host Disease as a Second-Line Therapy: A Multicentre, Randomized, Controlled Trial.” BMC Medicine 22 (1): 1–15. doi:10.1186/s12916-024-03275-5.